Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Four years after starting semaglutide, patients maintained an average weight loss of 10% of their body weight, a peer-reviewed 2024 study funded by Novo Nordisk found. Doctors say the drug’s ...

Weight loss drugs like Ozempic and Wegovy are all the rage, but not everyone can afford them, and not everyone needs them to lose weight. And for those people, when it comes to weight loss ...

Don't miss out on the headlines from Weight Loss. Followed categories will be ... the results of a major clinical trial that showed semaglutide 2.4 mg (sold as Wegovy) reduced cardiovascular ...